AU Patent

AU2020319662B2 — New pharmaceutical formulation

Assigned to F Hoffmann La Roche AG · Expires 2024-02-29 · 2y expired

What this patent protects

Disclosed herein are pharmaceutical compositions and dosage forms including N-[5-(3,5- difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4- ylamino) benzamide that are useful in the treatment of subjects having cancer. The present disclosure also…

USPTO Abstract

Disclosed herein are pharmaceutical compositions and dosage forms including N-[5-(3,5- difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4- ylamino) benzamide that are useful in the treatment of subjects having cancer. The present disclosure also provides methods for preparing these pharmaceutical compositions and dosage forms, and methods of treating subjects having cancer utilizing the pharmaceutical compositions and dosage forms provided herein.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020319662B2
Jurisdiction
AU
Classification
—
Expires
2024-02-29
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.